Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 1/20 | 0.53 |
| ▸ | FFAR2 | O15552 | 18/20 | 0.50 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29358752 | 0.86 | S1PR3 (0.46) | P2RY2FFAR2CCNE1CDK2CDK5 | |
| SCHEMBL21394890 | 0.86 | S1PR3 (0.46) | P2RY2FFAR2CCNE1CDK2CDK5 | |
| SCHEMBL21395232 | 0.86 | P2RY2 (0.43) | P2RY2FFAR2CCNE1CDK2CDK5 | |
| SCHEMBL21394896 | 0.85 | P2RY2 (0.42) | P2RY2FFAR2CCNE1CDK2CDK5 | |
| SCHEMBL34467551 | 0.85 | P2RY2 (0.42) | P2RY2FFAR2CCNE1CDK2CDK5 | |
| SCHEMBL21395055 | 0.83 | PSEN1 (0.42) | P2RY2FFAR2CCNE1CDK2CDK5 | |
| SCHEMBL29356948 | 0.81 | CCNE1 (0.47) | P2RY2CCNE1CDK2CDK5 | |
| SCHEMBL21394900 | 0.81 | CCNE1 (0.47) | P2RY2CCNE1CDK2CDK5 | |
| SCHEMBL34467357 | 0.81 | STAT3 (0.41) | P2RY2FFAR2CCNE1CDK2CDK5 | |
| SCHEMBL21395247 | 0.81 | PSEN1 (0.48) | P2RY2CCNE1CDK2CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138977-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | DEWPOINT THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12612396-B1 | Modulators of beta catenin and uses thereof | DEWPOINT THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20230078764-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-16 | — | — | US | disclosed |
| EP-3941908-A1 | COMPOUNDS AND USES THEREOF | Yumanity Therapeutics, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| WO-2020198026-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| WO-2019183587-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612396-B1 | Modulators of beta catenin and uses thereof | CTNNB1, CTNND1, CTNNA1 | P2RY2 4395/4885FFAR2 4798/4885CCNE1 447/4885 |
| US-20230078764-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | P2RY2 2029/4885FFAR2 4354/4885CCNE1 2527/4885 |
| US-20260138977-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | CTNNB1, CTNND1, CTNNA1 | P2RY2 4395/4885FFAR2 4798/4885CCNE1 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.